Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
OLAP
Cancer Type
Breast
Intent
Adjuvant
Regimen Category
Evidence-Informed
Funding Program
Exceptional Access Program
olaparib - For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative high risk early breast cancer, based on criteria
Drugs in Regimen
Regimen Monograph
Dec 2024
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: August 12, 2026
